|
시장보고서
상품코드
2110409
의료용 CDMO(개발 및 제조 수탁 기관) 시장 : 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Healthcare Contract Development and Manufacturing Organization Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
세계의 의료용 CDMO(개발 및 제조 수탁 기관) 시장 규모는 2025년 3,574억 8,000만 달러로 평가되었고, 2034년에는 1조 49억 5,000만 달러에 이를 것으로 예상되며, 2026-2034년 CAGR 12.17%로 성장할 전망입니다. 제약 회사와 생명공학 기업이 의약품 개발 및 제조 공정을 외부에 위탁하는 경향이 강해짐에 따라, 전 세계 의료용 CDMO(개발 및 제조 수탁 기관) 시장은 급속히 확대되고 있습니다. CDMO는 의약품 제형 개발, 임상시험용 시료 제조, 대규모 생산 등 폭넓은 서비스를 제공합니다. 이러한 외부 위탁 모델을 통해 기업은 운영 비용 절감, 효율성 향상, 그리고 새로운 치료법의 상용화 가속화를 도모할 수 있습니다.
CDMO 시장의 주요 성장 동인 중 하나는 의약품 개발의 복잡화와 전문적인 제조 능력에 대한 수요 증가입니다. 제약 기업들은 현대 의약품 생산에 필요한 첨단 기술과 규제에 관한 전문 지식을 활용하기 위해 CDMO와 제휴하고 있습니다. 또한, 바이오의약품 및 맞춤형 의료의 개발이 진행되고 있는 점도 전문적인 제조 서비스에 대한 수요를 더욱 부추기고 있습니다.
앞으로 제약 파이프라인의 확대가 지속됨에 따라 CDMO 시장은 크게 성장할 것으로 예측됩니다. 바이오 제조, 연속 공정 및 첨단 약물 전달 시스템 분야의 기술 혁신을 통해 생산 능력은 향상될 것입니다. 또한, 전 세계 제약 기업들이 전 세계적으로 제조 파트너십을 확대함에 따라 신흥 시장도 시장 성장에 중요한 역할을 할 것으로 예측됩니다.
당사의 보고서는 광범위한 산업 및 시장에 걸쳐 종합적이고 실행 가능한 인사이트를 제공할 수 있도록 세심하게 작성되었습니다. 각 보고서에는 시장 환경을 완벽하게 이해할 수 있도록 설계된 몇 가지 중요한 구성 요소가 포함되어 있습니다.
시장 개요 : 이 섹션에서는 주요 정의, 분류 및 현재 업계 동향에 대한 개요를 포함하여 시장에 대해 알기 쉽게 설명합니다.
시장 역학 : 시장 성장을 형성하는 주요 촉진요인, 억제요인, 기회 및 과제에 대한 상세한 평가입니다. 기술 개발, 규제 체계, 변화하는 업계 동향 등의 요인을 포괄합니다.
세분화 분석 : 제품 유형, 용도, 최종 사용자 및 지역을 기준으로 시장을 주요 부문으로 체계적으로 분류한 것입니다. 이 섹션에서는 각 부문의 실적, 성장 잠재력 및 시장 기여도를 밝힙니다.
경쟁 환경 : 주요 시장 진출기업에 대해 시장 내 위치, 제품 포트폴리오, 전략적 이니셔티브, 재무 실적 등을 포함하여 상세하게 평가합니다. 경쟁 동향 및 주요 기업이 채택하는 전략에 대한 귀중한 인사이트를 제공합니다.
시장 예측 : 지정된 예측 기간 동안 시장 규모 및 성장 패턴에 대한 데이터 기반 예측입니다. 이 섹션에서는 과거 동향, 현재 시장 상황 및 정량 분석을 반영하여 향후 예상되는 동향을 밝힙니다.
지역별 분석 : 주요 지리적 지역 시장 실적을 종합적으로 검토하고, 고성장 지역 및 지역별 동향을 파악함으로써 각 지역 고유 시장 기회를 더 깊이 이해할 수 있도록 합니다.
새로운 동향 및 기회 : 중요한 시장 동향, 기술 발전 및 새로운 투자 기회를 파악합니다. 이 섹션에서는 잠재적인 성장 분야와 미래의 업계 동향에 초점을 맞추었습니다.
맞춤형 옵션 : 고객의 요청에 따라 보고서를 유연하게 맞춤 설정해 드리는 서비스를 제공합니다. 여기에는 추가 세분화, 국가별 분석, 경쟁사 프로파일링, 맞춤형 데이터 포인트, 또는 특정 시장 부문에 초점을 맞춘 인사이트력 등이 포함되어, 전략적 의사결정을 보다 효과적으로 지원합니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 의료용 CDMO(개발 및 제조 수탁 기관) 시장 : 서비스 유형별
제5장 세계의 의료용 CDMO(개발 및 제조 수탁 기관) 시장 : 치료 영역별
제6장 세계의 의료용 CDMO(개발 및 제조 수탁 기관) 시장 : 개발 단계별
제7장 세계의 의료용 CDMO(개발 및 제조 수탁 기관) 시장 : 최종 사용자별
제8장 세계의 의료용 CDMO(개발 및 제조 수탁 기관) 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
AJY 26.08.20The global healthcare contract development and manufacturing organization market size is expected to reach USD 1004.95 Billion in 2034 from USD 357.48 Billion in 2025, growing at a CAGR of 12.17 during 2026-2034.The global healthcare contract development and manufacturing organization (CDMO) market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource drug development and manufacturing processes. CDMOs provide a range of services, including drug formulation, clinical trial material production, and large-scale manufacturing. This outsourcing model helps companies reduce operational costs, improve efficiency, and accelerate the commercialization of new therapies.
One of the primary drivers of the CDMO market is the growing complexity of drug development and the increasing demand for specialized manufacturing capabilities. Pharmaceutical companies are collaborating with CDMOs to access advanced technologies and regulatory expertise required for modern drug production. Additionally, the rising development of biologics and personalized medicines is further driving the need for specialized manufacturing services.
In the future, the CDMO market is expected to grow significantly as pharmaceutical pipelines continue to expand. Technological innovations in biomanufacturing, continuous processing, and advanced drug delivery systems will enhance production capabilities. Emerging markets are also expected to play a crucial role in market growth as global pharmaceutical companies expand their manufacturing partnerships worldwide.
Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:
Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.
Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.
Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.
Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.
Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.
Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.
Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.
Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.
MARKET SEGMENTATION
By Service Type
- Contract Development (Pre-formulation & Formulation Development, Process Development & Optimisation, Analytical, Stability & Release Testing)
- Contract Manufacturing (API Manufacturing, Finished Dosage Formulation, Packaging & Serialization Services, Medical Devices)
By Therapeutic Area
- Oncology
- Cardiovascular
- Infectious Diseases
- Neurology / CNS
- Auto-immune & Inflammatory
- Metabolic Disorders (Diabetes, Obesity)
- Rare & Orphan Diseases
- Other Therapeutic Areas
By Development Phase
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Commercial / Post-Approval
By End User
- Big / Large Pharmaceutical Companies
- Emerging & Virtual Biotech Firms
- Generic Drug Manufacturers
- Medical-Device & Combination-Product Firms
- Academic, Government & Non-Profit Sponsors
COMPANIES PROFILED
- AbbVie Inc. (AbbVie Contract, Manufacturing), AGC Inc. (AGC Biologics), C.H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim BioXcellence), Cambrex Corporation, Delpharm SAS, Fareva S.A., Flex Ltd. (Flex Health), FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies), Jabil Inc. (Jabil Healthcare), Jubilant Pharmova Limited (Jubilant HollisterStier), Lonza Group AG, Novo Holdings A/S (Catalent, Inc.), PCI Pharma Services (PCI Services LLC), Piramal Pharma Limited (Piramal Pharma Solutions), Recipharm AB, Samsung Biologics Co., Ltd., Sanmina Corporation, Siegfried Holding AG, Simtra BioPharma Solutions (divested from Baxter International Inc.), Thermo Fisher Scientific Inc. (Patheon), Vetter Pharma-Fertigung GmbH & Co. KG, WuXi AppTec Co., Ltd. (WuXi STA / WuXi ATU)
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY SERVICE TYPE 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Service Type
- 4.2. Contract Development (Pre-formulation & Formulation Development, Process Development & Optimisation, Analytical, Stability & Release Testing) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Contract Manufacturing (API Manufacturing, Finished Dosage Formulation, Packaging & Serialization Services, Medical Devices) Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Therapeutic Area
- 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.5. Neurology / CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.6. Auto-immune & Inflammatory Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.7. Metabolic Disorders (Diabetes, Obesity) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.8. Rare & Orphan Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.9. Other Therapeutic Areas Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY DEVELOPMENT PHASE 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Development Phase
- 6.2. Pre-clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.6. Commercial / Post-Approval Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY END USER 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast End User
- 7.2. Big / Large Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Emerging & Virtual Biotech Firms Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Generic Drug Manufacturers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.5. Medical-Device & Combination-Product Firms Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.6. Academic, Government & Non-Profit Sponsors Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY REGION 2022-2034 (USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Service Type
- 8.2.2 By Therapeutic Area
- 8.2.3 By Development Phase
- 8.2.4 By End User
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Service Type
- 8.3.2 By Therapeutic Area
- 8.3.3 By Development Phase
- 8.3.4 By End User
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Service Type
- 8.4.2 By Therapeutic Area
- 8.4.3 By Development Phase
- 8.4.4 By End User
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Service Type
- 8.5.2 By Therapeutic Area
- 8.5.3 By Development Phase
- 8.5.4 By End User
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Service Type
- 8.6.2 By Therapeutic Area
- 8.6.3 By Development Phase
- 8.6.4 By End User
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 AbbVie Inc. (AbbVie Contract Manufacturing)
- 10.2.2 AGC Inc. (AGC Biologics)
- 10.2.3 C.H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim BioXcellence)
- 10.2.4 Cambrex Corporation
- 10.2.5 Delpharm SAS
- 10.2.6 Fareva S.A
- 10.2.7 Flex Ltd. (Flex Health)
- 10.2.8 FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies)
- 10.2.9 Jabil Inc. (Jabil Healthcare)
- 10.2.10 Jubilant Pharmova Limited (Jubilant HollisterStier)
- 10.2.11 Lonza Group AG
- 10.2.12 Novo Holdings A/S (Catalent, Inc.)
- 10.2.13 PCI Pharma Services (PCI Services LLC)
- 10.2.14 Piramal Pharma Limited (Piramal Pharma Solutions)
- 10.2.15 Recipharm AB
- 10.2.16 Samsung Biologics Co.Ltd
- 10.2.17 Sanmina Corporation
- 10.2.18 Siegfried Holding AG
- 10.2.19 Simtra BioPharma Solutions (divested From Baxter International Inc.)
- 10.2.20 Thermo Fisher Scientific Inc. (Patheon)
- 10.2.21 Vetter Pharma-Fertigung GmbH & Co. KG
- 10.2.22 WuXi AppTec Co., Ltd. (WuXi STA / WuXi ATU)
